Table 1: Comparison of baseline data (following
stratification).
|
Variable |
SPIRO Group (n = 16) |
AMLO Group (n = 11) |
P-value (t-test) |
P-value (k-test) |
Effect size |
||
|
Age (years) |
43.8 |
11.1 |
45.5 |
12.6 |
0.707 |
0.778 |
- 0.156 |
|
weight (kg) |
90.6 |
10.3 |
89.1 |
8.6 |
0.686 |
0.544 |
0.141 |
|
BMI (kg/m2) |
35.3 |
3.3 |
35.5 |
2.6 |
0.885 |
0.66 |
- 0.049 |
|
Fasting plasma glucose (mg/dL) |
87.9 |
6.8 |
96.8 |
11 |
0.021 |
0.086 |
- 1.314 |
|
2 h-plasma glucose level OGTT
(mg/dL) |
106.5 |
22.3 |
123.9 |
41.6 |
0.202 |
0.028 |
- 0.781 |
|
HOMA-IR |
3.6 |
2.1 |
3.2 |
1.3 |
0.546 |
0.9 |
0.187 |
|
Total cholesterol (mg/dL) |
209.1 |
50.6 |
215.9 |
47.1 |
0.717 |
0.398 |
- 0.134 |
|
HDL-cholesterol (mg/dL) |
44.4 |
8.6 |
47 |
7.3 |
0.388 |
0.315 |
- 0.304 |
|
Triglycerides (mg/dL) |
195 |
84.8 |
193.2 |
115.9 |
0.964 |
0.778 |
0.021 |
|
CKD-EPI (ml/min/1.73 m2) |
100.2 |
19.2 |
98.4 |
22 |
0.921 |
0.996 |
0.095 |
|
Urinary albumin excretion (mg/g
creatinine) |
23.2 |
18.6 |
40.7 |
41.5 |
0.186 |
0.264 |
- 0.943 |
|
hs-CRP (mg/L) |
4.1 |
2.6-6.3 |
2.6 |
2.0-4.5 |
0.149 |
0.315 |
0.381 |
|
FMD (%) |
10 |
5.9 |
13.7 |
6.4 |
0.123 |
0.213 |
- 0.636 |
|
SBP 24 h (mmHg) |
146.2 |
15.1 |
152.5 |
20.5 |
0.38 |
0.398 |
- 0.415 |
|
DBP 24 h (mmHg) |
87.2 |
11.1 |
90.9 |
17.4 |
0.522 |
0.778 |
- 0.336 |
Values are
expressed as mean ± SD. Except for hs-CRP, it is expressed
as median (25-75% title).
OGTT: 75-g Oral
Glucose Tolerance Test; BMI: Body Mass Index; CPK-EPI: Chronic Kidney Disease-Epidemiology
Collaboration; hs-CRP: C Reactive Protein-high
sensitivity; DBP: Diastolic Blood Pressure; FMD: Flow Mediated Dilation; HDL:
High - Density Lipoprotein; HOMA IR: Homeostasis Model Assessment of Insulin
Resistance; SBP: Systolic Blood Pressure; SD: Standard Deviation